{"id":"tp-38849","type":"article-newspaper","title":"Argenx Projects $4B in 2026 R&D and SG&A Expenses, Eyes Up to Five 2027 U.S. Launches","author":"John Kim","publisher":"TOKENPOST Inc.","url":"https://www.tokenpost.com/news/business/38849","datePublished":"2026-10-23T08:57:46.000Z","dateModified":"2026-10-23T08:57:46.000Z","language":"en","abstract":"The 2026 estimate includes transaction-related costs for Forte Biosciences, while a possible empasiprubart launch depends on December trial results.","section":"Business","references":[]}